Gossamer Bio Q1 Earnings Call Highlights
Key takeaways
- Gossamer Bio Q1 Earnings Call Highlights Market Beat Mon, May 18, 2026 at 8:05 PM GMT+7 7 min read GOSS Key Points Interested in Gossamer Bio, Inc.?
- Gossamer Bio is still targeting a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, with a June FDA pre-NDA meeting set to help shape the filing.
- Gossamer believes the totality of evidence could support a differentiated label and commercial profile.
Gossamer Bio Q1 Earnings Call Highlights Market Beat Mon, May 18, 2026 at 8:05 PM GMT+7 7 min read GOSS Key Points Interested in Gossamer Bio, Inc.? Here are five stocks we like better.
Gossamer Bio is still targeting a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, with a June FDA pre-NDA meeting set to help shape the filing. Management said approval could potentially follow in the third quarter of 2027 if the process stays on track.
The company highlighted efficacy and imaging data from PROSERA and the CT-FRI sub-study, saying seralutinib showed a 13.3-meter placebo-adjusted improvement in six-minute walk distance and favorable signals across arterial, venous and fibrosis-like imaging measures. Gossamer believes the totality of evidence could support a differentiated label and commercial profile.